QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (Devonian or the Corporation) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, provides further details on previously announced results of Thykamine Phase 2 clinical trial for the treatment of mild-to-moderate atopic dermatitis (AD).
In this 4-week, phase 2, randomized, double-blind, multicentre, placebo-controlled study, adult patients with mild-to-moderate AD were randomized to receive Thykamine cream 0.05%, 0.10%, 0.25% or vehicle cream (placebo) twice daily. The primary efficacy endpoint was the Investigator Global Assessment (IGA) success rate defined as percentage of patients with an IGA score of 0 or 1 with greater than or equal to 2-grade reduction at week 4. Secondary endpoints included Body Surface Area (BSA) and Eczema Area and Severity Index (EASI). A total of 162 patients, spread over several sites in Canada, were recruited for this study.
IGA success rates at week 4 were 6.7% for placebo (vehicle cream), 19.0% for Thykamine cream 0.05% (p=0.053 vs placebo), 30.8% Thykamine cream 0.10% (p=0.014 vs placebo) and 12.1% for Thykamine cream 0.25% (p=0.461 vs placebo). Success rate over placebo of Thykamine cream 0.1% was not only reached at week 4 but also at week 3 (p = 0.04), resulting in a fast onset of the therapeutic effect. As such, Thykamine cream 0.10% has been retained for Phase 3 trials.
In addition, Thykamine achieved statistically significant differences, compared to placebo, in its key secondary efficacy endpoint, i.e. BSA.
Lastly, Thykamine was well-tolerated, as very few adverse events were reported.
"The efficacy of Thykamine obtained in this clinical trial was as expected and compared favourably to published results of other therapeutic products such as the phosphodiesterase inhibitors (PDE4)1,2 and calcineurin inhibitors,3 demonstrating that a Botanical Drug candidate can be as potent as a product derived from chemical synthesis." said Dr Andr P. Boulet, President and CEO of Devonian. "With the successful completion of this dose ranging study, we can now move into phase 3 clinical development in the adult patients. We are also planning a clinical trial within the pediatric patient population" added Dr Boulet.
Grant of Stock Options
In addition, the Company announces that the Board of Directors has approved the grant of 60,000 stock options (the "Options") to a member of the Board of Directors. These options are exercisable on the grant date, at a price of $ 0.20, for a period of 10 years.
About Atopic Dermatitis (AD)
AD, also known as eczema, is a type of inflammation of the skin. It results in itchy, red, swollen, and cracked skin that may lead to secondary infection. The condition typically starts in childhood with changing severity over the years. Although the cause of AD is unknown, it is believed to involve genetics, a compromised immune system and can be triggered by environmental factors. AD is the most common skin disease4 and its prevalence continues to increase worldwide. In the United States, the incidence has been reported to be 10-20% of children with new diagnoses at almost 11% per year5. The severity of AD can be categorized into three stages, mild, moderate, and severe. The mild and moderate forms constitute approximately 67% and 26% respectively of the AD childhood patient population. A similar distribution has been reported in the adult patient population (71% and 26% respectively) 6,7. There is currently an enormous unmet need for new, effective, and well-tolerated treatment options in AD8.
About Thykamine
Thykamine, the first pharmaceutical product issued from Devonians SUPREX platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis. Thykamine is currently under development as treatment for ulcerative colitis and atopic dermatitis. Both Thykamine and SUPREX platform are protected by several patents in North America, Europe and Asia.
About Devonian
Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonians focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Qubec, Canada where it owns a state-of-the art extraction facility with full traceability from the seed to the pill. Acquired in 2018, Altius Healthcare Inc., its commercialization partner, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXv:GSD).
For more information, visit http://www.groupedevonian.com
References
Forward Looking Statements
This press release contains forward-looking statements about Devonians objectives, strategies and businesses that involve risks and uncertainties. These statements are forward-looking because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonians ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonians prospectus dated April 21st, 2017 under the heading Risk Factors related to Devonians business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Read the original post:
Devonian Health Group Provides More Details on Previously Announced Positive Topline Results From Phase 2 Clinical Trial of Thykamine in Adult...
- Retrospective analysis of 397 DABE | CCID - Dove Medical Press - December 3rd, 2023 [December 3rd, 2023]
- Derm In The News: November 26-December 2 - Dermatology Times - December 3rd, 2023 [December 3rd, 2023]
- When is the Best Time to Try Alternative Treatments for Eczema? - National Eczema Association - September 23rd, 2023 [September 23rd, 2023]
- How Eczema Negatively Impacted the Way She Talked to Herself - National Eczema Association - September 23rd, 2023 [September 23rd, 2023]
- Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black ... - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Combination Treatments in HS Require Further Review - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Addressing Misconceptions, Concerns Around Biosimilar Use - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Native American and Indigenous Communities Face Dermatologic ... - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- Microwave Therapy Successful for Treating Warts in Children - Dermatology Times - September 23rd, 2023 [September 23rd, 2023]
- 9 Best Antifungal Body Washes Review - The Jerusalem Post - September 23rd, 2023 [September 23rd, 2023]
- Patients With Severe Psoriasis Have Higher Risk of Heart Disease ... - AJMC.com Managed Markets Network - September 23rd, 2023 [September 23rd, 2023]
- Swimming and skin: What to know if a child has eczema - Harvard Health - May 20th, 2023 [May 20th, 2023]
- Experts demand traffic-light labels to show strength of eczema cream - Daily Mail - May 20th, 2023 [May 20th, 2023]
- Its mosquito season. Here are tips for treating bites, preventing them in the first place - Yahoo News - May 20th, 2023 [May 20th, 2023]
- How new EU incentives will help all patients get the best treatments - Euronews - May 20th, 2023 [May 20th, 2023]
- Consistent Use of Ceramide-Containing Products Combined With ... - Dermatology Times - May 20th, 2023 [May 20th, 2023]
- The Best Swimming Skin and Hair Products | livestrong - Livestrong - May 20th, 2023 [May 20th, 2023]
- These 13 Household Items Contain Smells That Are Harmful To ... - Rock 92.9 - May 20th, 2023 [May 20th, 2023]
- FDA Approves First Pill to Treat Moderate-to-Severe Crohn Disease - HealthDay News - May 20th, 2023 [May 20th, 2023]
- Feds investigating eczema cream after two Oregon babies found with high levels of lead in blood - OregonLive - January 27th, 2023 [January 27th, 2023]
- Heres how to treat eczema and other skin conditions for cold weather - The Hindu - January 27th, 2023 [January 27th, 2023]
- Atopic eczema - NHS - November 23rd, 2022 [November 23rd, 2022]
- Seborrheic dermatitis - Symptoms and causes - Mayo Clinic - November 23rd, 2022 [November 23rd, 2022]
- Oatmeal skincare is the perfect solution for sensitive skin (+ best products to try) - Lifestyle Asia Singapore - November 23rd, 2022 [November 23rd, 2022]
- Eczema - StatPearls - NCBI Bookshelf - October 21st, 2022 [October 21st, 2022]
- Cold, dry weather can trigger eczema - how to reduce damage to the skin this winter - Express - October 21st, 2022 [October 21st, 2022]
- Eczema on lips nhs - kved.erxe.de - August 29th, 2022 [August 29th, 2022]
- xrfkc.vitalhaskap.pl - August 29th, 2022 [August 29th, 2022]
- Atopic eczema and alopecia areata - cyasn.kugel-lernfoerderung.de - August 29th, 2022 [August 29th, 2022]
- north shore zipline oahu - owk.tophouse.shop - August 29th, 2022 [August 29th, 2022]
- nak stock - vbi.maxense.shop - August 29th, 2022 [August 29th, 2022]
- Atopic eczema and alopecia areata - zayqif.hydra-market.shop - August 29th, 2022 [August 29th, 2022]
- fort worth map with zip codes - prxrzj.rids-gear.shop - August 29th, 2022 [August 29th, 2022]
- Ear Eczema: Symptoms, Causes, and Treatments - Healthgrades - August 29th, 2022 [August 29th, 2022]
- The Mutha Body Oil Is Worth the Splurge, Especially If You Have Sensitive Skin - POPSUGAR - August 29th, 2022 [August 29th, 2022]
- Are You Allergic to Your Beauty Products? A Patch Test Might Tell You - Allure - August 29th, 2022 [August 29th, 2022]
- Stinky sweat turns out to have a surprising health benefit : Goats and Soda - NPR - August 29th, 2022 [August 29th, 2022]
- Makeup for Eczema-Prone Skin: Considerations, Products, and Tips - Healthline - July 13th, 2022 [July 13th, 2022]
- Eczema Vaccinatum: Symptoms, Diagnosis, and Treatment - Healthline - July 13th, 2022 [July 13th, 2022]
- What Is Topical Steroid Withdrawal in Atopic Dermatitis Treatment? - Everyday Health - July 13th, 2022 [July 13th, 2022]
- A new 'cure for eczema' pill has been signed off but who is allowed to take it? - Cosmopolitan UK - July 13th, 2022 [July 13th, 2022]
- What Causes Dandruff And How To Get Rid Of It, According To A Dermatologist - Fatherly - July 13th, 2022 [July 13th, 2022]
- Allergies on the rise due to climate change - BusinessWorld Online - July 13th, 2022 [July 13th, 2022]
- Cryotherapy Treatment: Uses and Benefits - newschannelnebraska.com - July 13th, 2022 [July 13th, 2022]
- Mutations of Filaggrin Leading to Eggs & Milk Allergies - Physician's Weekly - June 18th, 2022 [June 18th, 2022]
- How AI & the Pandemic Are Changing the Skin & Hair Clinic Experience - The Quint FIT - June 18th, 2022 [June 18th, 2022]
- How to treat your childs dry skin in winter - Lowvelder - June 15th, 2022 [June 15th, 2022]
- Topical steroid: Types, uses, side effects and treatment as revealed by doctors - Hindustan Times - June 15th, 2022 [June 15th, 2022]
- Psoriasis in the Belly Button: Symptoms, Causes, and Treatment - Healthline - June 15th, 2022 [June 15th, 2022]
- In his last days, my father asked for Yiddish music - Forward - June 15th, 2022 [June 15th, 2022]
- Throwing away the water after cooking rice? Know how it could benefit your skin and hair - Times Now - June 15th, 2022 [June 15th, 2022]
- Family 'devastated and numb' as boy, 9, dies a day after breaking his arm - Coventry Live - June 15th, 2022 [June 15th, 2022]
- Happy Cappy Not Just For Babies; Everyone With Sensitive Skin Can Benefit - Pediatric Shampoo Granted Trademark in New Campaign: 'No Scalp Left... - June 15th, 2022 [June 15th, 2022]
- Eczema on black skin: Pictures, symptoms, and treatment - June 11th, 2022 [June 11th, 2022]
- Eczema on the Ears or Eyebrows: How to Cope - Everyday Health - June 11th, 2022 [June 11th, 2022]
- What People With Eczema Need to Know About Self-Screening for Skin Cancer - National Eczema Association - June 11th, 2022 [June 11th, 2022]
- How to protect children with eczema from scratching until they bleed - Channel NewsAsia - June 11th, 2022 [June 11th, 2022]
- Autism, allergies and other diseases and disorders afflicted baby boomers, too - PolitiFact - June 11th, 2022 [June 11th, 2022]
- Is saltwater good for the skin? What to know Beaufort South Carolina The Island News - The Island News - June 11th, 2022 [June 11th, 2022]
- What's trending? The most-read stories on APAC beauty market and consumer insights - CosmeticsDesign-Asia.com - June 11th, 2022 [June 11th, 2022]
- Canada to require a warning be printed on every cigarette - Coventry Live - June 11th, 2022 [June 11th, 2022]
- Holistic Acne Treatments That Are Better Than What You've Been Doing - The List - June 11th, 2022 [June 11th, 2022]
- Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials - PR Newswire UK - June 7th, 2022 [June 7th, 2022]
- Woman left balding and bedbound by chronic eczema clears the condition with a 9 face cream - The Independent - June 7th, 2022 [June 7th, 2022]
- Poll: Six in 10 people would eat food that has fallen on the floor - Coventry Live - June 7th, 2022 [June 7th, 2022]
- The itch that rashes: Treating and understanding eczema - El Paso Inc. - June 5th, 2022 [June 5th, 2022]
- Celebrities With Eczema Speak Out - Everyday Health - June 5th, 2022 [June 5th, 2022]
- Lotion, Cream, Gel, and Ointment Similarly Effective for Childhood Eczema - HealthDay News - June 5th, 2022 [June 5th, 2022]
- Antibiotics Given Before C-sections Are Not Linked to Asthma, Eczema in Young Children - Pharmacy Times - June 5th, 2022 [June 5th, 2022]
- Eczema Skin-Care Products Market Size, Scope and Forecast | Alliance Pharma Plc., Bausch Health Companies Inc., Bayer AG., AbbVie Inc., Eli Lilly and... - June 5th, 2022 [June 5th, 2022]
- What are the benefits of ceramides for the skin? - Medical News Today - June 5th, 2022 [June 5th, 2022]
- Some Allergies Associated With Lower Risk of SARS-CoV-2 Infection - Smithsonian Magazine - June 5th, 2022 [June 5th, 2022]
- The CDC is sending monkeypox vaccines to people at high risk in a race to prevent the spread - CNBC - June 5th, 2022 [June 5th, 2022]
- Missing Sikeston teen may be heading to Kansas City area - KMBC Kansas City - June 5th, 2022 [June 5th, 2022]
- Should you cleanse or exfoliate first? What to know - Medical News Today - June 5th, 2022 [June 5th, 2022]
- Dry Skin: Eczema, Itchy Skin, Causes, Treatments, Relief, Types - May 17th, 2022 [May 17th, 2022]
- Foods to Eat and Foods to Avoid If You Have Eczema - The Beet - May 17th, 2022 [May 17th, 2022]
- 3 Women With Eczema Describe the Ways They Combat Nighttime Flare-Ups - Verve Times - May 17th, 2022 [May 17th, 2022]
- The Challenges of Parenting a Child With Eczema - Verve Times - May 17th, 2022 [May 17th, 2022]
- Manuka Honey Benefits for Skin: Benefits, Masks, and More - Greatist - May 17th, 2022 [May 17th, 2022]